Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRA_17693 is an experimental small molecule compound that acts as an inhibitor of Serine protease 1 (PRSS1), also known as cationic trypsinogen. It has been characterized by its activity against various synthetic substrates, including Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec, and Boc-Val-Pro-Arg-Mec. The compound is identified by the chemical formula C24H17FN4O5 and a molecular weight of 460.414 Da. While listed in databases such as DrugBank (DB01741), CRA_17693 is primarily utilized as a research tool in structural biology and biochemical studies to investigate protease-ligand interactions, particularly in the context of trypsin inhibition. There are currently no known clinical indications or commercial development partners associated with this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CRA_17693.